Alectinib Hydrochloride

證據等級: L5

預測適應症: 0 個

Alectinib Hydrochloride: No TxGNN Predictions Available — Analysis on Hold

One-Sentence Summary

Alectinib hydrochloride is a selective ALK/RET tyrosine kinase inhibitor, internationally approved (as Alecensa®) for the treatment of ALK-positive non-small cell lung cancer (NSCLC). However, the current Evidence Pack contains no TxGNN predicted indications, making a formal repurposing evaluation impossible at this stage. All key data inputs — including mechanism of action, safety warnings, and drug-disease predictions — are absent; a Hold decision is recommended until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	No data available in this Evidence Pack
Predicted New Indication	No TxGNN predictions available
TxGNN Prediction Score	N/A
Evidence Level	N/A
Taiwan Market Status	✗ Not Marketed (0 TFDA licenses)
Number of Authorizations	0
Recommended Decision	Hold

Why Repurposing Analysis Cannot Proceed

The Evidence Pack for alectinib hydrochloride is critically incomplete in three independent dimensions.

First, the predicted_indications array is empty — TxGNN has returned zero drug-disease repurposing candidates for this compound. Without a target indication, none of the downstream analyses (clinical trial evidence, literature review, mechanism plausibility) can be executed. This is a structural blocker: the entire report template is predicated on at least one TxGNN prediction existing.

Second, the mechanism of action field is flagged as a high-severity data gap (DG002). Alectinib is known in the published literature as a second-generation ALK inhibitor that suppresses ALK, RET, and ROS1 kinase activity, with CNS penetration superior to first-generation agents. However, because this information is not present in the Evidence Pack itself, it cannot be formally cited in a mechanism-plausibility argument for any repurposing candidate.

Third, all safety fields — key warnings, contraindications, and drug-drug interactions — are absent (DG001, Blocking severity). This prevents even the most basic safety screen required before proceeding to Stage 1 evaluation.

Critical Data Gaps

Gap ID	Category	Missing Item	Severity	Remediation
DG001	Drug Level	Package insert warnings and contraindications	Blocking	Download SmPC PDF from TFDA or EMA website and parse
DG002	Drug Level	Mechanism of Action (MOA)	High	Query DrugBank API using INN “alectinib”
—	Prediction Layer	TxGNN predicted indications	Blocking	Re-run TxGNN prediction pipeline; confirm drug node mapping for alectinib hydrochloride
—	Identity	DrugBank ID	High	Required for all downstream collector calls (DDI, toxicity, MOA)

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no TxGNN predicted indications and is missing all safety and mechanistic data. A repurposing evaluation cannot be performed without a target disease and a minimum viable safety profile.

To proceed, the following is needed:

Re-run the TxGNN prediction pipeline to generate drug-disease candidates for alectinib hydrochloride, and verify that the drug node is correctly mapped in the knowledge graph
Resolve the DrugBank ID (the query log confirms a successful DrugBank hit on 2026-03-26 — retrieve and store the ID)
Use the DrugBank ID to populate mechanism of action and toxicity data (DG002)
Retrieve the EU SmPC or TFDA package insert to populate warnings and contraindications (DG001)
Re-generate the Evidence Pack once the above four items are complete, then proceed with standard L1–L5 evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.